<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml">

  <head>
    <title>Special Blood Components</title>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1">
    <link rel="stylesheet" href="http://code.jquery.com/mobile/1.4.4/jquery.mobile-1.4.4.min.css" />
    <link rel="stylesheet" href="http://maxcdn.bootstrapcdn.com/font-awesome/4.2.0/css/font-awesome.min.css">
    <link rel="stylesheet" href="app.css">
    <link href="http://themergency.com/footable-demo/css/footable-0.1.css" rel="stylesheet" type="text/css" />
    <link href="http://themergency.com/footable-demo/css/footable.sortable-0.1.css" rel="stylesheet" type="text/css" />
  </head>

  <body>
    
    <div class="overlay">
      
    	<div class="overlay-container" id="terms">
        <h3 class="headerlogo"><i class="fa fa-ln glow">&#xf043;</i> Special Blood Components Terms of Use
        </h3>
    		<div class="textbox">
        <p><strong>
    		 By pressing the 'Accept and continue' button, you indicate that you have
    		 read and consent to the Terms of Use.</strong>
    		</p>
    		<h3>Terms of Use</h3>
        <h4>
          Purpose and audience
        </h4>
        <p>
          Special Blood Components ("the app") aims to make it easy to learn about
          the correct use of irradiated and cytomegalovirus (CMV) negative blood
          components in patients with special transfusion requirements.
          It is designed for:
        </p>
        <ul>
          <li>Doctors who prescribe and request blood transfusions.
          </li>
          <li>Nurses and midwives who administer or prescribe transfusions.
          </li>
          <li>Biomedical scientists who process blood requests.
          </li>
          <li>Medical trainees who may be required to undertake any of the above.
          </li>
        </ul>
        
        <h4>
          Evidence base
        </h4>
        
        <p>
          The app is based on the British Committee for Standards in Haematology (BCSH)
          2010 guidelines on the irradation of blood components and the 2012 position 
          statement on the use of CMV negative blood components by the Advisory 
          Committee on the Safety of Blood, Tissues and Organs (SaBTO).
        </p>
        
        <h4>
          Data protection
        </h4>
        
        <p>
          The app is developed as part of a research project seeking to evaluate and improve the design
          of medical apps. The use of the app is therefore monitored using Google Analytics.
          To do this we store a browser cookie on your device. The following data is recorded:
        </p>
        
        <ul> 
          <li>Which pages you visit and for how long.</li>
          <li>Information about your computing device (operating system, screen resolution, browser, IP address).</li>
          <li>Your approximate geographical location (country, city).</li>
        </ul>
        
        <p>
          This data is only available to the researchers, but analysis of the data
          may be presented in academic publications observing academic good practice,
          such as protecting confidentiality through pseudonymisation and anonymisation.
        </p>
        
        <h4>
          Disclaimer
        </h4>
        
        <p>
          The app was created during a PhD research project at the University of 
          Edinburgh and is available for evaluation only. There may be inaccuracies in 
          the content. Guidance may not be appropriate in all patient situations and
          local hospital policies may differ.</p>
          
        <p> 
          The app is not intended to be a substitute for local hospital guidelines,
          professional medical judgement, advice, diagnosis, or treatment. The app
          publishers, developers and contributors do not take any legal resposibility
          for harm resulting from the use of the app. Use your own critical judgement
          and always put patient safety first.
        </p>
        
        <h4>No warranty</h4>
        
        <p>
          THE APP IS PROVIDED "AS IS", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR
          IMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,
          FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE
          AUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER
          LIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,
          OUT OF OR IN CONNECTION WITH THE APP OR THE USE OR OTHER DEALINGS IN THE
          APP.
        </p>
    		</div>
    		<a href="#" onclick="$('.overlay').slideUp('slow');" class="ui-btn ui-shadow ui-corner-all ui-btn-a">Accept and continue</a>
    		
    		<h2 class="mainlogo hidden">
    		  <i class="fa fa-5x glow">&#xf043;</i>
          <br/>Special Blood Components
        </h2>
          
      </div>
  	</div>
  	
  	
    <div data-role="page" id="home" data-title="Special Blood Components">
      
      <div data-role="header" class="inactive" data-theme="b">
        
        <h3 class="headerlogo active" style="font-size: 1.3em"><i class="fa fa-ln glow">&#xf043;</i> Special Blood Components
        </h3>
        <div class="submenu inactive hidden">
          <p style="margin: 0;">
          v.0.2. Updated 5/11/2015
            <a href="#searchdialog" data-rel="dialog" data-transition="slidedown" data-role="button">QuickFind <i class="fa fa-ln">&#xf002;</i></a>
          </p>
        </div>
      </div>

      <div role="main" class="ui-content">
    
    		<h2 class="mainlogo hidden">
    		  <i class="fa fa-5x glow">&#xf043;</i>
          <br/>Special Blood Components
        </h2>

        <a data-role="button" href="#learn" class="infobox">
           <i class="fa fa-fw fa-2x button-icon">&#xf19d;</i>
           <strong>Learn</strong><br/>
           Why should patients recieve irradiated or CMV-negative blood components?
        </a>
        
        <a data-role="button" href="#indications" class="infobox">
           <i class="fa fa-fw fa-2x button-icon">&#xf0f1;</i>
           <strong>Indications</strong><br/>
           Which patients require irradiated or CMV-negative blood components?
        </a>
        
        <a data-role="button" href="#quickfind" class="infobox">
           <i class="fa fa-fw fa-2x button-icon">&#xf002;</i>
           <strong>QuickFind</strong><br/>
           Search across the app.
        </a>
        
        <a data-role="button" href="#glossary" class="infobox hidden">
           <i class="fa fa-fw fa-2x button-icon">&#xf02e;</i>
           <strong>Glossary</strong><br/>
           Look up a word in the index.
        </a>
        
        <a data-role="button" href="#references" class="hidden infobox">
           <i class="fa fa-fw fa-2x button-icon">&#xf02d;</i>
           <strong>References</strong><br/>
           Browse evidence cited in the app.
        </a>
        
        <a data-role="button" href="#about"  class="infobox">
           <i class="fa fa-2x button-icon">&#xf05a;</i>
           <strong>About the app</strong><br/>
           Find out more details about this app.
        </a>
        
      </div>
      <div data-role="footer" data-position="fixed" data-tap-toggle="false" data-theme="b">
        <div data-role="navbar">
          <ul>
            <li><a href="#home" class="navtab active"><i class="fa fa-2x glow">&#xf015;</i> Home</a>
            </li>
            <li><a href="#learn" class="navtab inactive"><i class="fa fa-2x">&#xf19d;</i>Learn</a>
            </li>
            <li><a href="#indications" class="navtab inactive"><i class="fa fa-2x">&#xf0f1;</i> Indications</a>
            </li>
          </ul>
        </div>
      </div>
    </div>
    
    
    
    <div data-role="page" id="indications" data-title="Indications for irradiated and CMV negative blood components">
      <div data-role="header" class="inactive" data-theme="b">
        
        <h3 class="headerlogo active"><i class="fa fa-ln glow">&#xf0f1;</i> Indications for irradiated and CMV negative blood components
        </h3>
        <div class="submenu inactive">
          <a href="#" data-role="button" data-rel="back" class="float-left"><i class="fa fa-ln">&#xf053;</i> Back</a>
          <a href="#quickfind" data-role="button">QuickFind <i class="fa fa-ln">&#xf002;</i></a>
        </div>
      </div>
      
      <div role="main" class="ui-content">
        <h3>Which patients require irradiated or CMV-negative blood components?</h3>
        <p>Press an indication to show details.</p>
       
        <div id="indications-filter">
          <button data-inline="true" onclick="$('#filterlist').val('').selectmenu('refresh');$('table').trigger('footable_clear_filter');$('#indicationsearch').toggle(); $('#indications-filter').toggle(); $('#filter-text').focus();"><i class="fa fa-ln">&#xf002;</i> Search table</button>
          <select id="filterlist" data-inline="true" class="fa-select" data-overlay-theme="b" data-theme="a" data-icon="false" data-native-menu="false">
            <option value="">&#xf0b0; Filter</option>
            <option value="">All indications</option>
            <option value="#xf043">&#xf043; Blood Components</option>
            <option value="#xf0c3">&#xf0c3; Immunosuppressive Drugs</option>
            <option value="#xf0f6">&#xf0f6; Medical History & Conditions</option>
            <option value="#xf1ae">&#xf1ae; Neonatology & Obstetrics</option>
            <option value="#xf0ec">&#xf0ec; Stem Cell & Bone Marrow</option>
          </select>
        </div>
    
        <div id="indicationsearch" class="hidden" style="background: #FFE; border:1px solid #ccc; border-radius: 5px; padding: 4px; margin-bottom: 1em;">
          <a href="#" style="display: inline-block; margin: 0; float:right;" data-role="button" id="close-indication-search" onclick="$('#filterlist').val('').selectmenu('refresh'); $('#indicationsearch').toggle(); $('#indications-filter').toggle(); $('table').trigger('footable_clear_filter');">Close <i class="fa fa-ln">&#xf00d;</i></a>
          <p style="">
            <strong>Enter a search term. Results will show instantly.</strong>
          </p>
          <input id="filter-text" style="line-height: 1em;" type="text" />
        </div>

        <table class="footable" id="indicationstable" data-filter="#filter-text">
          <thead>
            <tr>
              <th data-class="expand" class="centered">Indication
              </th>
              <th>
              </th>
              <th data-hide="phone" class="centered">Irradiation
              </th>
              <th data-hide="phone" class="centered">CMV-negative
              </th>
              <th data-hide="all" class="summary-guidance">
              </th>
              <th data-hide="all" class="referenced-guidance"></th>
            </tr>
          </thead>
          <tbody>
          </tbody>
        </table>
        <a href="#" data-role="button" data-theme="b" onclick="$(window).scrollTop(0);" class="active">Back to top <i class="fa fa-ln">&#xf0d8;</i></a>
      </div>
      <div data-role="footer" data-position="fixed" data-tap-toggle="false" data-theme="b">
        <div data-role="navbar">
          <ul>
            <li><a href="#home" class="navtab inactive"><i class="fa fa-2x">&#xf015;</i> Home</a>
            </li>
            <li><a href="#learn" class="navtab inactive"><i class="fa fa-2x">&#xf19d;</i>Learn</a>
            </li>
            <li><a href="#indications" class="navtab active"><i class="fa fa-2x glow">&#xf0f1;</i> Indications</a>
            </li>
          </ul>
        </div>
      </div>
    </div>
    
    
    <div data-role="page" id="learn" data-title="Learn about Special Blood Components">
      
      <div data-role="header" class="inactive" data-theme="b">
        
        <h3 class="headerlogo active"><i class="fa fa-ln glow">&#xf19d;</i> Learning objectives
        </h3>
        <div class="submenu inactive">
          <a href="#home" data-role="button" data-rel="back" class="float-left"><i class="fa fa-ln">&#xf053;</i> Back</a>
          <a href="#ta-gvhd" data-role="button">Next <i class="fa fa-ln">&#xf054;</i></a>
          <a href="#quickfind" data-role="button">QuickFind <i class="fa fa-ln">&#xf002;</i></a>
        </div>
      </div>

      <div role="main" class="ui-content">
      
        <h2>Learning objectives</h2>
        
        <p>
          This section explains the rationale for the use of irradiated, leucodepleted and
          CMV-negative blood components in preventing TA-GvHD and TT-CMV.
        </p>
        
        
        <p>After reviewing the learning material you should be able to:
        </p>
        <ul>
          <li><p>List the risk factors for TA-GvHD and explain the role of leucodepletion and irradiation in mitigating them.</p></li>
          <li><p>Describe the causes and consequences of TT-CMV infection, how it is prevented and identify patients who are at risk.</p></li>
          <li><p>Consider mistakes involving patients who have special requirements and strategies to improve patient safety.</p></li>
        </ul>
        
        <h3>Learning material outline</h3>
        
        <a href="#" style="padding: 0.8em;" data-role="button" data-theme="b" class="hidden active" onclick="$('.toc').toggle('slow');"><i class="fa fa-ln">&#xf0c9;</i> Table of contents</a>
       
        <div class="toc">
          <ul data-role="listview" data-inset="true" data-dividertheme="b">
            <li data-theme="b"><a class="active" href="#learn">Learning objectives</a></li>
            <li><a href="#ta-gvhd">Transfusion-Associated Graft versus Host Disease (TA-GvHD)</a></li>
            <li><a href="#tt-cmv">Transfusion-Transmitted Cytomegalovirus (TT-CMV)</a></li>
            <li><a href="#error">Errors in the Provision of Special Requirements</a></li>
            <li><a href="#summary">Learning Summary</a></li>
            <li><a href="#reference">References and Further Reading</a></li>
          </ul>
        </div>
        
        
        <a href="#home" style="padding: 0.8em;" data-role="button" data-theme="b" data-inline="true" data-rel="back" class="active"><i class="fa fa-ln">&#xf053;</i> Back</a>
        <a href="#ta-gvhd" style="float:right; padding: 0.8em;" data-role="button" data-theme="b" data-inline="true" class="active">Next <i class="fa fa-ln">&#xf054;</i></a>
        
        <a href="#" data-role="button" data-theme="b" onclick="$(window).scrollTop(0);" class="active">Back to top <i class="fa fa-ln">&#xf0d8;</i></a>

      </div>
      <div data-role="footer" data-position="fixed" data-tap-toggle="false" data-theme="b">
        <div data-role="navbar">
          <ul>
            <li><a href="#home" class="navtab inactive"><i class="fa fa-2x">&#xf015;</i> Home</a>
            </li>
            <li><a href="#learn" class="navtab active"><i class="fa fa-2x glow">&#xf19d;</i>Learn</a>
            </li>
            <li><a href="#indications" class="navtab inactive"><i class="fa fa-2x">&#xf0f1;</i> Indications</a>
            </li>
          </ul>
        </div>
      </div>
    </div>
    
    
    <div data-role="page" id="objectives" data-title="Learning objectives">
      
      <div data-role="header" class="inactive" data-theme="b">
        
        <h3 class="headerlogo active"><i class="fa fa-ln glow">&#xf19d;</i> 1.1 Learning objectives
        </h3>
        <div class="submenu inactive">
          <a href="#home" data-role="button" data-rel="back" class="float-left"><i class="fa fa-ln">&#xf053;</i> Back</a>
          <a href="#ta-gvhd" data-role="button">Next <i class="fa fa-ln">&#xf054;</i></a>
          <a href="#quickfind" data-role="button">QuickFind <i class="fa fa-ln">&#xf002;</i></a>
        </div>
      </div>

      <div role="main" class="ui-content">
      
        <div class="hidden">

          <h3>Key learning points</h3>
          <p>You have completed the section. Summary of the key learning points:</p>
          <ul>
            <li><p>Transfusion associated graft versus host disease (TA-GvHD) is a rare fatal complication of transfusion that is preventable by irradiating components.</p></li>
            <li><p>Transfusion of Cytomegalovirus (CMV) positive blood can cause life long disability in at risk patients (e.g. neonates and fetuses) who should receive components tested negative to CMV (CMV-negative).</p></li>
          </ul>
          
          <h3>
            Key points
          </h3>
          
          <p>
            Failure to provide <a href="javascript:%20showWord('irradiation')" class=
            "definition">irradiated</a> cellular <a href=
            "javascript:%20showWord('components')" class="definition">blood components</a>
            may expose <a href="javascript:showWord('at-risk')" class="definition">at-risk
            patients</a> to transfusion-associated Graft versus Host Disease <a href=
            "javascript:%20showWord('gvhd')" class="definition">TA-GvHD</a>. This is a very
            rare, but life-threatening condition <a href=
            "javascript:%20showSource('bcsh2010');" class="reference">BCSH 2010, p.37</a>.
          </p>
          <p>
            Red cells and platelets supplied through the UK Blood Services are <a href=
            "javascript:%20showWord('leucodepletion')" class="definition">leucocyte
            depleted</a> <a href="javascript:%20showSource('bcsh2010');" class=
            "reference">SaBTO 2012, p.1</a>. However removal of leucocytes (white cells) is
            not a substitute for irradiation, which prevents TA-GvHD by inactivating residual
            donor lymphocytes <a href="javascript:%20showSource('bcsh2010');" class=
            "reference">BCSH 2010, p.49</a>.
          </p>
          <p>
            Although leucodepletion provides significant protection against <a href=
            "javascript:%20showWord('cmv')" class="definition">cytomegalovirus</a> (CMV)
            infection, cellular blood components should be provided as CMV negative to
            protect vulnerable patients against transfusion-transmitted CMV infection
            <a href="javascript:%20showSource('sabto2012');" class="reference">SaBTO
            2012</a>.
          </p>
          
        </div>
        
        <h3>1.1 Learning objectives</h3>
        
        <p>After reviewing the information in this section you should be able to:
        </p>
        <ul>
          <li><p>List the risk factors for TA-GvHD and explain the role of leucodepletion and irradiation in mitigating them.</p></li>
          <li><p>Describe what TT-CMV is and how it is prevented, as well as identify patients who are at risk.</p></li>
          <li><p>Be aware of and critically reflect upon the complex reasons for mistakes involving patients who have special requirements.</p></li>
        </ul>
        
        
        <a href="#home" style="padding: 0.8em;" data-role="button" data-theme="b" data-inline="true" data-rel="back" class="active"><i class="fa fa-ln">&#xf053;</i> Back</a>
        <a href="#ta-gvhd" style="float:right; padding: 0.8em;" data-role="button" data-theme="b" data-inline="true" class="active">Next <i class="fa fa-ln">&#xf054;</i></a>
        
        <h3>Navigation</h3>
        
        <p>Select a topic below to jump to that section or use the back and next navigation buttons.</p>
        
        <a href="#" style="padding: 0.8em;" data-role="button" data-theme="b" class="hidden active" onclick="$('.toc').toggle('slow');"><i class="fa fa-ln">&#xf0c9;</i> Table of contents</a>
       
        <div class="toc">
          <ul data-role="listview" data-inset="true" data-dividertheme="b">
            <li data-theme="b"><a href="#learn" class="active" data-theme="b">1.1 Learning objectives</a></li>
            <li><a href="#ta-gvhd">1.2 Transfusion-associated Graft versus Host Disease</a></li>
            <li><a href="#tt-cmv">1.3 Transfusion-transmitted Cytomegalovirus infection</a></li>
            <li><a href="#error">1.4 Errors in provision of special requirements</a></li>
            <li><a href="#summary">1.5 Summary</a></li>
            <li><a href="#reference">1.6 Further reading</a></li>
          </ul>
        </div>
        
        <a href="#" data-role="button" data-theme="b" onclick="$(window).scrollTop(0);" class="active">Back to top <i class="fa fa-ln">&#xf0d8;</i></a>
        

      </div>
      <div data-role="footer" data-position="fixed" data-tap-toggle="false" data-theme="b">
        <div data-role="navbar">
          <ul>
            <li><a href="#home" class="navtab inactive"><i class="fa fa-2x">&#xf015;</i> Home</a>
            </li>
            <li><a href="#learn" class="navtab active"><i class="fa fa-2x glow">&#xf19d;</i>Learn</a>
            </li>
            <li><a href="#indications" class="navtab inactive"><i class="fa fa-2x">&#xf0f1;</i> Indications</a>
            </li>
          </ul>
        </div>
      </div>
    </div>
    
    
    
    <div data-role="page" id="ta-gvhd" data-title="Transfusion-Associated Graft versus Host Disease (TA-GvHD)">
      
      <div data-role="header" class="inactive" data-theme="b">
        
        <h3 class="headerlogo active"><i class="fa fa-ln glow">&#xf19d;</i>Transfusion-Associated Graft versus Host Disease (TA-GvHD)
        </h3>
        <div class="submenu inactive">
          <a href="#learn" data-role="button" data-rel="back" class="float-left"><i class="fa fa-ln">&#xf053;</i> Back</a>
          <a href="#tt-cmv" data-role="button">Next <i class="fa fa-ln">&#xf054;</i></a>
          <a href="#quickfind" data-role="button">QuickFind <i class="fa fa-ln">&#xf002;</i></a>
        </div>
      </div>

      <div role="main" class="ui-content" data-searchable="3">
        
        <h2>Transfusion-Associated Graft versus Host Disease (TA-GvHD)</h2>
        
        <p>
          TA-GvHD is a rare fatal disease caused by the transfusion of cellular
          blood (red cells, platelets and granulocytes) components containing
          viable lymphocytes. The transfused donor lymphocytes engraft and
          attack the recipient, causing skin rash, diarrhoea, liver disease,
          bone marrow failure and death from infection within two-three weeks of
          the transfusion <span class="evidence" title="htm2007">(HTM 2007, p.41)</span> <span class="evidence" title="bcsh2010">(BCSH 2010, p.41)</span>.
        </p>

        <h3>Risk factors and prevention</h3>

        <p>
          Normally a recipient's immune system will identify and destroy the
          transfused lymphocytes, preventing TA-GvHD. The success of the immune
          response depends on three factors <span class="evidence" title="bcsh2010">(BCSH 2010, p.37)</span>:
        </p>
        
        <ul>
          <li><p>The number and viability of lymphocytes transfused.</p></li>
          <li><p>The susceptibility of the recipient's immune system to their engraftment.</p></li>
          <li><p>The degree of immunological (HLA) disparity between donor and patient.</p></li>
        </ul>

        <h3>Irradiation inactivates viable donor lymphocytes</h3>
        
        <p>
          TA-GvHD can be prevented by exposing cellular blood components
          to a dose of 25-50Gy Gamma or X-ray irradiation as this inactivates the
          donor lymphocytes <span class="evidence" title="bcsh2010">(BCSH 2010, p.41)</span>.
          
        </p>
        
        <h3>Reducing the number of lymphocytes through leucodepletion</h3>
        
        <p>
          All platelets and red cells blood are leucodepleted in the UK, significantly
          reducing the number of lymphocytes in these components. Only two cases of 
          TA-GvHD have been reported in the UK following the introduction of universal
          leucodepletion in 1999, despite many hundred reports of at risk patients failing to 
          be provided with irradiated blood products. This suggest leucodepletion may be 
          effective in preventing TA-GvHD, although it is not a replacement for irradiation.
          <span class="evidence" title="bcsh2010">(BCSH 2010, p.41)</span>.
        </p>

        
        <h3>Indications for irradiated blood components</h3>
        
        <p>
        
          Only cellular blood components given to at risk patients.
          
          Granulocytes cannot be leucodepleted and is full of active lymphocytes.
  
          Only cellular blood components contain lymphocytes. Fresh Frozen Plasma
          (FFP), cryoprecipitate and plasma products do not need to be irradiated.
          (BCSH 2010, p.36)
          
          TA-GvHD can also occur in immunocompetent recipients if their immune
          system is unable to identify the donor lymphocytes.
      
        </p>
        
        <h3>Immunodeficiency</h3>
        
        
        <h3>Immunological disparity (HLA)</h3>
        
        <p>
          Identification depends on differences in the human leucocyte antigens 
          (HLA) between donor and recipient. TA-GvHD occurs when there is a one way 
          HLA match between the donor and recipient, which can occur in transfusions
          between relatives or HLA-matched transfusions (see figure).
        </p>

        <a href="#" data-role="button" data-inline="true" onclick="$('#hla-figure').toggle('slow')">Figure: One way HLA match</a>
        
        <div class="hidden" id="hla-figure">
          
          <p>Click image to change size.</p>
          
          <div style="overflow-x: scroll;">
            <img onclick="$(this).toggleClass('big-image').toggleClass('small-image')" class="small-image" src="hla-vertical.png"/>
          </div>
          
          <p style="line-height: 1.1em;">
            The blood donor is homozygous for an HLA haplotype (red) for which the 
            recipient is heterozygous (red and blue).
          </p>
        </div>
        
        <h3>Navigation</h3>
        
        <a href="#" style="padding: 0.8em;" data-role="button" data-theme="b" class="hidden active" onclick="$('.toc').toggle('slow');"><i class="fa fa-ln">&#xf0c9;</i> Table of contents</a>
       
        <div class="toc">
          <ul data-role="listview" data-inset="true" data-dividertheme="b">
            <li><a href="#learn">1.1 Learning objectives</a></li>
            <li data-theme="b"><a href="#ta-gvhd" class="active">1.2 Transfusion-associated Graft versus Host Disease</a></li>
            <li><a href="#tt-cmv">1.3 Transfusion-transmitted Cytomegalovirus infection</a></li>
            <li><a href="#error">1.4 Errors in provision of special requirements</a></li>
            <li><a href="#summary">1.5 Summary</a></li>
            <li><a href="#reference">1.6 Further reading</a></li>
          </ul>
        </div>
        
        <a href="#learn" style="padding: 0.8em;" data-role="button" data-theme="b" data-inline="true" data-rel="back" class="active"><i class="fa fa-ln">&#xf053;</i> Back</a>
        <a href="#tt-cmv" style="float:right; padding: 0.8em;" data-role="button" data-theme="b" data-inline="true" class="active">Next <i class="fa fa-ln">&#xf054;</i></a>
        
        <a href="#" data-role="button" data-theme="b" onclick="$(window).scrollTop(0);" class="active">Back to top <i class="fa fa-ln">&#xf0d8;</i></a>
        
      </div>
      <div data-role="footer" data-position="fixed" data-tap-toggle="false" data-theme="b">
        <div data-role="navbar">
          <ul>
            <li><a href="#home" class="navtab inactive"><i class="fa fa-2x">&#xf015;</i> Home</a>
            </li>
            <li><a href="#learn" class="navtab active"><i class="fa fa-2x glow">&#xf19d;</i>Learn</a>
            </li>
            <li><a href="#indications" class="navtab inactive"><i class="fa fa-2x">&#xf0f1;</i> Indications</a>
            </li>
          </ul>
        </div>
      </div>
    </div>
    
    
    
    <div data-role="page" id="tt-cmv" data-title="Transfusion transmitted CMV infection">
      
      <div data-role="header" class="inactive" data-theme="b">
        
        <h3 class="headerlogo active"><i class="fa fa-ln glow">&#xf19d;</i> Transfusion-Transmitted Cytomegalovirus (TT-CMV)
        </h3>
        <div class="submenu inactive">
          <a href="#ta-gvhd" data-role="button" data-rel="back" class="float-left"><i class="fa fa-ln">&#xf053;</i> Back</a>
          <a href="#error" data-role="button">Next <i class="fa fa-ln">&#xf054;</i></a>
          <a href="#quickfind" data-role="button">QuickFind <i class="fa fa-ln">&#xf002;</i></a>
        </div>
      </div>

      <div role="main" class="ui-content" data-searchable="3">
            
        <h2>Transfusion-Transmitted Cytomegalovirus (TT-CMV)</h2>
        
          <p>
  
            Cytomegalovirus (CMV) is a herpes virus that cause a chiefly asymptomatic infection in
            healthy people. About half the UK population is CMV positive and many blood
            donors carry the virus. The virus occur freely in blood plasma during active
            infection and remains latent in monocytes following infection <span class="evidence" title="sabto2012b">(SaBTO 2012, p.5)</span>.

          </p>
        
        <a href="#" data-role="button" data-inline="true" onclick="$('#cmv-figure').toggle('slow')">Figure: CMV micrograph</a>
        
        <div class="figure hidden" id="cmv-figure">
          
          
          <div style="overflow-x: scroll;">
            <img onclick="$(this).toggleClass('big-image').toggleClass('small-image')" class="small-image" src="cmv-tem.jpg"/>
          </div>
          
          <p>
            200x transmission electron micrograph (TEM). Cytomegalovirus virions are present
            as intranuclear inclusion bodies ('owl eyes'). Public domain image courtesy of The 
            Public Health Image Library <span class="evidence" title="phil1986">(PHIL 1986)</span>.
            Click image to resize.
          </p>
        </div>
        
        <h3>Risk groups</h3>
          
          <p>
  
            CMV infection often go unnoticed in immunocompetent patients, but it can be fatal
            or cause lifelong disability in fetuses, neonates and immunocompromised patients
            <span class="evidence" title="sabto2012">(SaBTO 2012, p.1)</span>.
            Neonatal mortality from CMV infection is 10-30% (higher in preterms) and the virus
            accounts for 12% of all sensorineural hearing loss and 10% of cerebral palsy
            <span class="evidence" title="sabto2012">(SaBTO 2012, p.4)</span>.

          </p>
          
          
        <h3>Prevention</h3>
        
        <p>
          CMV is a cell-associated virus and can be present in cellular blood 
          components (red cells, platelets and granulocytes). TT-CMV infection is
          prevented by removing leucocytes from red cells and platelets through
          leucodepletion and by providing at risk patients with blood from donors
          who screen negative for CMV antibody <span class="evidence" title="sabto2012">(SaBTO 2012)</span>.
        </p>

        <h3>Leucodepletion</h3>

        <p>
          Leucodepletion is the removal of white cells, usually by filtration, from red cells and
          platelets. This process is particularly effective in removing monocytes, where latent
          CMV may be present <span class="evidence" title="sabto2012">(SaBTO 2012, p.2)</span>.
          Since 1999 all platelets and red cells produced in the UK are leucodepleted. Universal
          leucodepletion has significantly reduced the chance of TT-CMV infection,
          but not completely eliminated it and at risk patients should receive blood
          from CMV-negative screened donors <span class="evidence" title="sabto2012">(SaBTO 2012)</span>.
        </p>

        <h3>Who should receive CMV-negative blood?</h3>

        <p>
          CMV-negative blood is indicated for intra-uterine and neonatal transfusions 
          (up to 28 days post expected date of delivery) <span class="evidence" title="sabto2012">
          (SaBTO 2012, p. 6)</span>. If a pregnant mother is infected or re-infected 
          with CMV there is a high chance of transmission of the virus to the baby <span class="evidence" title="sabto2012">(SaBTO 2012, p. 6)</span>.
          Therefore, pregnant women, regardless of their CMV serostatus, who receive 
          elective transfusions should receive CMV-negative blood <span class="evidence" title="sabto2012">(SaBTO 2012, p. 6)</span>. But it is not 
          required during labour and delivery. If in an emergency CMV-negative blood
          is unavailable, leucodepleted blood should be used instead <span class="evidence" title="sabto2012">(SaBTO 2012, p. 11)</span>.
          Finally, CMV-negative components should be provided to seronegative patients
          receiving granulocytes, as these cannot be leucodepleted.
        </p>

        <p>
          For all other patients, including patients with HIV, organ transplant
          and haemopoetic stem cell transplant patients, the use of leucodepleted components
          provides adequate protection against TT-CMV <span class="evidence" title="sabto2012">(SaBTO 2012, p. 11)</span>.. 
        </p>
        
        <h3>Navigation</h3>
        
        <a href="#" style="padding: 0.8em;" data-role="button" data-theme="b" class="hidden active" onclick="$('.toc').toggle('slow');"><i class="fa fa-ln">&#xf0c9;</i> Table of contents</a>
       
        <div class="toc">
          <ul data-role="listview" data-inset="true" data-dividertheme="b">
            <li><a href="#learn">1.1 Learning objectives</a></li>
            <li><a href="#ta-gvhd">1.2 Transfusion-associated Graft versus Host Disease</a></li>
            <li data-theme="b"><a href="#tt-cmv" class="active">1.3 Transfusion-transmitted Cytomegalovirus infection</a></li>
            <li><a href="#error">1.4 Errors in provision of special requirements</a></li>
            <li><a href="#summary">1.5 Summary</a></li>
            <li><a href="#reference">1.6 Further reading</a></li>
          </ul>
        </div>
        
        <a href="#ta-gvhd" style="padding: 0.8em;" data-role="button" data-theme="b" data-inline="true" data-rel="back" class="active"><i class="fa fa-ln">&#xf053;</i> Back</a>
        <a href="#error" style="float:right; padding: 0.8em;" data-role="button" data-theme="b" data-inline="true" class="active">Next <i class="fa fa-ln">&#xf054;</i></a>
        
        <a href="#" data-role="button" data-theme="b" onclick="$(window).scrollTop(0);" class="active">Back to top <i class="fa fa-ln">&#xf0d8;</i></a>
        
        
      </div>
      <div data-role="footer" data-position="fixed" data-tap-toggle="false" data-theme="b">
        <div data-role="navbar">
          <ul>
            <li><a href="#home" class="navtab inactive"><i class="fa fa-2x">&#xf015;</i> Home</a>
            </li>
            <li><a href="#learn" class="navtab active"><i class="fa fa-2x glow">&#xf19d;</i>Learn</a>
            </li>
            <li><a href="#indications" class="navtab inactive"><i class="fa fa-2x">&#xf0f1;</i> Indications</a>
            </li>
          </ul>
        </div>
      </div>
    </div>
    
    
    
    <div data-role="page" id="error" data-title="Mistakes involving special requirements">
      
      <div data-role="header" class="inactive" data-theme="b">
        
        <h3 class="headerlogo active"><i class="fa fa-ln glow">&#xf19d;</i> Errors in the provision of special requirements
        </h3>
        <div class="submenu inactive">
          <a href="#tt-cmv" data-role="button" data-rel="back" class="float-left"><i class="fa fa-ln">&#xf053;</i> Back</a>
          <a href="#summary" data-role="button">Next <i class="fa fa-ln">&#xf054;</i></a>
          <a href="#quickfind" data-role="button">QuickFind <i class="fa fa-ln">&#xf002;</i></a>
        </div>
      </div>

      <div role="main" class="ui-content" data-searchable="3">
            
        <h2>Errors in the provision of special requirements</h2>
        
        <p>
          In the last five years, more than five hundred mistakes involving irradiated
          and CMV negative blood components were reported to the Serious Hazards of
          Transfusion (SHOT) UK haemovigilance scheme (see figure).
          To put this in perspective, almost three million blood components are issued annually in UK
          <a href="javascript:%20showSource('shot2009');" class="reference">SHOT 2009, p.11</a>, 
          of which approximately 10% are irradiated <a href="javascript:%20showSource('shot2010');" class="reference">SHOT 2010, p.129</a>.
          These were incidents where blood components failed to be provided as irradiated
          and/or CMV negative to at-risk patients according to guidelines.
        </p>
        
        <a href="#" data-role="button" data-inline="true" onclick="$('#errorgraph').toggle('slow')">Graph of mistakes reported to SHOT.</a>
        
        <div class="hidden" id="errorgraph">
          
          <p>Click image to change size.</p>
          
          <div style="overflow-x: scroll;">
            <img onclick="$(this).toggleClass('big-image').toggleClass('small-image')" class="small-image" src="http://optimalblooduse.eu/app/graph.png"/>
          </div>
          
          <p style="line-height: 1.1em;">
            <b>Figure:</b> Specific Requirements Not Met (SRNM) reports by year and
            source of error. Clinical errors include failure to communicate the need for
            special components to the lab. Lab errors are when the request was made but not
            acted upon <a href="javascript:%20showSource('shot2010');" class=
            "reference">SHOT 2010, p.27</a>. SHOT data used with permission and provided
            courtesy of Dr. Paula Bolton-Maggs, Debbi Poles and Alison Watts.
          </p>
        </div>
        
        
        <h2>
          What are some of the causes for mistakes?
        </h2>
        
        <p>
          There are many underlying reasons for why special requirements fail to be
          provided to at-risk patients, as these SHOT cases illustrate (select to expand):
        </p>
        
        <div data-role="collapsible-set">
          <div data-role="collapsible" data-collapsed-icon="alert">
            <h3>
              Poor knowledge of the indications
            </h3>
            <p>
              "The admitting doctor noted the past history of Hodgkin's disease but was
              not aware of the requirements for irradiated blood." <a href=
              "javascript:%20showSource('shot2011');" class="reference">SHOT 2011,
              p.26</a>
            </p>
          </div>
          <div data-role="collapsible" data-collapsed-icon="alert">
            <h3>
              Request form not filled out correctly
            </h3>
            <p>
              "A request form for blood components for a patient with CLL on fludarabine
              was completed by a haematology nurse, and checked and signed by a junior
              doctor who also prescribed the components. The need for irradiated blood
              was not indicated on the request form or the prescription." <a href=
              "javascript:%20showSource('shot2008');" class="reference">SHOT 2008,
              p.46</a>
            </p>
          </div>
          <div data-role="collapsible" data-collapsed-icon="alert">
            <h3>
              Failure to check medical record
            </h3>
            <p>
              "An elderly man was transfused 9 units of blood for chronic anaemia.
              Subsequently a haematology registrar found that he had been treated with
              cladarabine several years before." <a href=
              "javascript:%20showSource('shot2012');" class="reference">SHOT 2012,
              p.32</a>
            </p>
          </div>
          <div data-role="collapsible" data-collapsed-icon="alert">
            <h3>
              Shared patient care
            </h3>
            <p>
              "A patient was transferred from his primary hospital, where he had
              undergone a stem-cell transplant, to another hospital within the same Trust
              in order to access an ITU bed. [...] Irradiated components were not
              requested due to a lack of communication between the clinicians, and the
              laboratory records were separate from those at the originating hospital."
              <a href="javascript:%20showSource('shot2010');" class="reference">SHOT
              2010, p.41</a>
            </p>
          </div>
          <div data-role="collapsible" data-collapsed-icon="alert">
            <h3>
              Wrong blood component transfused
            </h3>
            <p>
              "No patient identification was taken to the blood fridge, and as a result
              the wrong unit of red cells was removed by a registered nurse and taken to
              the ward for an 81-year-old female patient with chronic lymphocytic
              leukaemia (CLL). On the ward another nurse administering the transfusion
              assumed that the checks had been completed, and because of this assumption
              no bedside checks were performed. The patient received non-irradiated group
              A D positive red cells, instead of irradiated O D positive red cells. The
              error was noticed when the patient asked whether the unit was irradiated.
              Consequently &lt;50 mL was transfused." <a href=
              "javascript:%20showSource('shot2008');" class="reference">SHOT 2008,
              p.31</a>
            </p>
          </div>
          <div data-role="collapsible" data-collapsed-icon="alert">
            <h3>
              Incorrect use of warning flags
            </h3>
            <p>
              "A patient required irradiated blood because of previous chemotherapy. The
              transfusion laboratory had received notification of this special
              requirement and added the information to the LIMS. The special requirement
              flag was subsequently removed from the LIMS in error. From the time the
              flag was removed to the time it was discovered, the patient had received 15
              units of red cells and 5 units of platelets that had not been irradiated."
              <a href="javascript:%20showSource('shot2012');" class="reference">SHOT
              2012, p.56</a>
            </p>
          </div>
        </div>
                
        <h2>
          How can mistakes be prevented?
        </h2>
        
        <p>
          SHOT has made several recommendations aimed at reducing mistakes, including:
        </p>
        
        <div data-role="collapsible-set">
          <div data-role="collapsible" data-collapsed-icon="check">
            <h3>
              Increase knowledge of special requirements
            </h3>
            <p>
              "All haematology units must devise specific educational programmes for all
              their staff members providing the rationale and indications for specialist
              components and this information should be accessible at the time of making
              the requests for blood components." <a href=
              "javascript:%20showSource('shot2011');" class="reference">SHOT 2011,
              p.28</a>
            </p>
            <p>
              "The importance of irradiation, and the rationale behind it should be
              emphasised during teaching of junior haematology and oncology doctors. This
              education is part of the curriculum for specialist trainees, but the junior
              pre-specialist doctors in these areas may remain ignorant despite being
              frequently called upon to order components." <a href=
              "javascript:%20showSource('shot2008');" class="reference">SHOT 2008,
              p.26</a>
            </p>
          </div>
          <div data-role="collapsible" data-collapsed-icon="check">
            <h3>
              Ensure special blood components are ordered correctly
            </h3>
            <p>
              "Local mechanisms for ordering and prescribing components need to
              facilitate correct ordering, and remind clinical and laboratory personnel
              where possible" <a href="javascript:%20showSource('shot2011');" class=
              "reference">SHOT 2011, p.26</a>
            </p>
          </div>
          <div data-role="collapsible" data-collapsed-icon="check">
            <h3>
              Educate patients who have special requirements
            </h3>
            <p>
              "Patients who require irradiated and other special products should be
              provided with an appropriate card [...] Patients with cards noting special
              requirements should be educated about their meaning and importance, in
              particular always to show these to clinical staff on admission to any
              hospital." <a href="javascript:%20showSource('shot2012');" class=
              "reference">SHOT 2012, p.34</a>
            </p>
          </div>
          <div data-role="collapsible" data-collapsed-icon="check">
            <h3>
              Conduct thorough bedside checks
            </h3>
            <p>
              "The final 'bedside' check is the last opportunity to ensure that the
              correct unit or component has been collected for the patient receiving the
              transfusion. Complete and thorough bedside checks involving one or two
              staff members must be completed independently and without interruption. "
              <a href="javascript:%20showSource('shot2011');" class="reference">SHOT
              2013, p.61</a>
            </p>
            <p>
              "Every person in the transfusion process must perform rigorous identity
              checks at each point and ensure that the component collected is the one
              prescribed. The use of a transfusion checklist is recommended." <a href=
              "javascript:%20showSource('shot2011');" class="reference">SHOT 2013,
              p.62</a>
            </p>
          </div>
          <div data-role="collapsible" data-collapsed-icon="check">
            <h3>
              Use warning flags with care
            </h3>
            <p>
              "Computer prompts/warnings/flags are a valuable tool for trying to prevent
              human error through 'slips'; but staff must also have the underpinning 
              knowledge to understand and act appropriately to a warning." <a href=
              "javascript:%20showSource('shot2011');" class="reference">SHOT 2012,
              p.7</a>
            </p>
            <p>
              "The addition of these warnings/flags/notes is a manual procedure and is
              itself prone to error and should be controlled, for example, entered by one
              BMS and checked by a second." <a href=
              "javascript:%20showSource('shot2011');" class="reference">SHOT 2012,
              p.51</a>
            </p>
                
          </div>
        </div>
        <p>
          Press to expand list items.
        </p>
        <p>
          For more details and recommendations, please refer to the latest SHOT
          report. <a href="javascript:%20showSource('shot2013');" class=
          "reference">SHOT 2013</a>
        </p>
        
        <h3>Navigation</h3>
        
        <a href="#" style="padding: 0.8em;" data-role="button" data-theme="b" class="hidden active" onclick="$('.toc').toggle('slow');"><i class="fa fa-ln">&#xf0c9;</i> Table of contents</a>
       
        <div class="toc">
          <ul data-role="listview" data-inset="true" data-dividertheme="b">
            <li><a href="#learn">1.1 Learning objectives</a></li>
            <li><a href="#ta-gvhd">1.2 Transfusion-associated Graft versus Host Disease</a></li>
            <li><a href="#tt-cmv">1.3 Transfusion-transmitted Cytomegalovirus infection</a></li>
            <li data-theme="b"><a href="#error" class="active">1.4 Errors in provision of special requirements</a></li>
            <li><a href="#summary">1.5 Summary</a></li>
            <li><a href="#reference">1.6 Further reading</a></li>
          </ul>
        </div>
        
        <a href="#tt-cmv" style="padding: 0.8em;" data-role="button" data-theme="b" data-inline="true" data-rel="back" class="active"><i class="fa fa-ln">&#xf053;</i> Back</a>
        <a href="#summary" style="float:right; padding: 0.8em;" data-role="button" data-theme="b" data-inline="true" class="active">Next <i class="fa fa-ln">&#xf054;</i></a>
        
        <a href="#" data-role="button" data-theme="b" onclick="$(window).scrollTop(0);" class="active">Back to top <i class="fa fa-ln">&#xf0d8;</i></a>
        
        
      </div>
      <div data-role="footer" data-position="fixed" data-tap-toggle="false" data-theme="b">
        <div data-role="navbar">
          <ul>
            <li><a href="#home" class="navtab inactive"><i class="fa fa-2x">&#xf015;</i> Home</a>
            </li>
            <li><a href="#learn" class="navtab active"><i class="fa fa-2x glow">&#xf19d;</i>Learn</a>
            </li>
            <li><a href="#indications" class="navtab inactive"><i class="fa fa-2x">&#xf0f1;</i> Indications</a>
            </li>
          </ul>
        </div>
      </div>
    </div>
    
        
    
    <div data-role="page" id="summary" data-title="Summary">
      
      <div data-role="header" class="inactive" data-theme="b">
        
        <h3 class="headerlogo active"><i class="fa fa-ln glow">&#xf19d;</i> 1.5 Learning summary </h3>
        <div class="submenu inactive">
          <a href="#summary" data-role="button" data-rel="back" class="float-left"><i class="fa fa-ln">&#xf053;</i> Back</a>
          <a href="#quickfind" data-role="button">QuickFind <i class="fa fa-ln">&#xf002;</i></a>
        </div>
      </div>

      <div role="main" class="ui-content" data-searchable="3">
            
        <h3>
          1.5 Learning summary
        </h3>
    
        <p>Having reviewed the information in this section you should know that:
        </p>
        <ul>
          <li><p><span class="evidence" title="Transfusion Associated Graft versus Host Disease">TA-GvHD</span> is a rare lethal complication of transfusion.</p></li>
          <li><p>TA-GvHD risk factors are transfusion of viable lymphocytes, recipient immunodeficiency and one way HLA match between donor and recipient</p></li>
          <li><p><span class="evidence" title="Irradiation inactivates donor lymphocytes that cause TA-GvHD.">Gamma or x-ray irradiation</span> is the accepted way of preventing TA-GvHD.</p></li>
          <li><p>Transfusion can transmit <span class="evidence" title="Cytomegalovirus">CMV</span> infection, leading to fatal or serious conditions in at risk patients.</p></li>
          <li><p>CMV-negative blood is indicated for intra-uterine and neonatal transfusions, elective transfusions during pregnancy and granulocyte transfusions to CMV-negative patients.</p></li>
          <li><p>For all other patients, leucodepletion provide sufficient protection against CMV.</p></li>
          <li><p>Mistakes can frequently lead to patients with special requirements not receiving irradiated or CMV-negative blood components.</p></li>
        </ul>
        
        <h3>Navigation</h3>
        
        <a href="#" style="padding: 0.8em;" data-role="button" data-theme="b" class="hidden active" onclick="$('.toc').toggle('slow');"><i class="fa fa-ln">&#xf0c9;</i> Table of contents</a>
       
        <div class="toc">
          <ul data-role="listview" data-inset="true" data-dividertheme="b">
            <li><a href="#learn">1.1 Learning objectives</a></li>
            <li><a href="#ta-gvhd">1.2 Transfusion-associated Graft versus Host Disease</a></li>
            <li><a href="#tt-cmv">1.3 Transfusion-transmitted Cytomegalovirus infection</a></li>
            <li><a href="#error" >1.4 Errors in provision of special requirements</a></li>
            <li><a href="#summary">1.5 Summary</a></li>
            <li data-theme="b"><a href="#reference" class="active">1.6 Further reading</a></li>
          </ul>
        </div>
        
        <a href="#tt-cmv" style="padding: 0.8em;" data-role="button" data-theme="b" data-inline="true" data-rel="back" class="active"><i class="fa fa-ln">&#xf053;</i> Back</a>
        <a href="#summary" style="float:right; padding: 0.8em;" data-role="button" data-theme="b" data-inline="true" class="active">Next <i class="fa fa-ln">&#xf054;</i></a>
        
        <a href="#" data-role="button" data-theme="b" onclick="$(window).scrollTop(0);" class="active">Back to top <i class="fa fa-ln">&#xf0d8;</i></a>
        
        
      </div>
      
      <div data-role="footer" data-position="fixed" data-tap-toggle="false" data-theme="b">
        <div data-role="navbar">
          <ul>
            <li><a href="#home" class="navtab inactive"><i class="fa fa-2x">&#xf015;</i> Home</a>
            </li>
            <li><a href="#learn" class="navtab active"><i class="fa fa-2x glow">&#xf19d;</i>Learn</a>
            </li>
            <li><a href="#indications" class="navtab inactive"><i class="fa fa-2x">&#xf0f1;</i> Indications</a>
            </li>
          </ul>
        </div>
      </div>
    </div>
    
    
    
    <div data-role="page" id="glossary" data-title="Glossary">
      
      <div data-role="header" class="inactive" data-theme="b">
        
        <h3 class="headerlogo active"><i class="fa fa-ln glow">&#xf19d;</i>Glossary </h3>
        <div class="submenu inactive">
          <a href="#summary" data-role="button" data-rel="back" class="float-left"><i class="fa fa-ln">&#xf053;</i> Back</a>
          <a href="#quickfind" data-role="button">QuickFind <i class="fa fa-ln">&#xf002;</i></a>
        </div>
      </div>

      <div role="main" class="ui-content" data-searchable="3">
            
        <h1>
          Glossary
        </h1>
        <div id="glossarylist">
        
          <h4>Blood components</h4>
          <p id="bloodcomponents">
            Blood is separated into five components <span class="evidence" title="htm2007">(HTM 2007, p.1)</span>:
            <br/>1. Red cells
            <br/>2. Platelets
            <br/>3. White cells
            <br/>4. Fresh frozen plasma (FFP)
            <br/>5. Cryoprecipitate
            <br/><br/>
            These can be classified into cellular and non-cellular (plasma) components.
          </p>
          
          <h4>Blood components, cellular</h4>
          <p id="cellularblood">
            Platelets, red cells and white cells are cellular blood components
            that contain leucocytes (white cells). Both TA-GvHD and TT-CMV are 
            associated with cellular blood components.
            <br/><br/>
            Cellular blood components, even if leucodepleted, must be irradiated to
            deactivate any residual lymphocytes before transfusion to at-risk patients
            <span class="evidence" title="bcsh2010">(BCSH 2010)</span>.
            <br/><br/>
            The only exception to this rule is cryopreserved red cells after deglycerolization,
            because these have been frozen and washed free of leucocytes 
            <span class="evidence" title="bcsh2010">(BCSH 2010, p42)</span>.
            <br/><br/>
            Monocytes, another type of white cell present in cellular blood components, 
            can carry latent cytomegalovirus (CMV). For this it is recommended that cellular 
            blood components be provided leucodepleted and CMV-negative to high risk patients
            <span class="evidence" title="sabto2012">(SaBTO 2012)</span>.
          </p>
          
          
          <h4>Blood components, non-cellular (plasma)</h4>
          <p id="cellularblood">
            Fresh frozen plasma, cryoprecipitate and fractionated plasma products
            are non-cellular blood components that do not contain white cells.
            <br/><br/>
            Non-cellular blood components do not need to be irradiated or 
            provided as CMV negative, eventhough CMV can occur freely in plasma
            during active CMV infections <span class="evidence" title="sabto2012">
            (SaBTO 2012, p.2)</span>.
          </p>
          
          <h4>Cytomegalovirus, Transfusion-Transmitted (TT-CMV)</h4>
          
          <p id="cytomegalovirus">
            "Cytomegalovirus is a herpes virus that gives rise to chronic, 
            persistent and, for the most part, asymptomatic infection in a
            majority of adults worldwide. More severe disease may occur in 
            certain groups, such as foetuses, neonates and immunocompromised
            adults." <span class="evidence" title="sabto2012">(SaBTO 2012, p.1)</span>
            <br/><br/>
            "Cytomegalovirus (CMV) infection can cause serious morbidity in
            immunocompromised CMV-negative patients. The risk can be minimised
            by the use of CMV-antibody-negative (seronegative) blood components.
            Leucocyte depletion also confers some protection since the virus is
            associated with white blood cells."
            <span class="evidence" title="htm2007">(HTM 2007, p.41)</span>
          </p>
          
          <h4>CMV-negative blood</h4>
          
          <p id="cmg-negative">
            CMV-negative blood refers to blood collected from from donors
            who tested negative for CMV antibody at the time of transfusion.
            CMV-negative components are indicated for patients at risk of
            TT-CMV
            </p>
          
          
          <h4>First- or second-degree relatives</h4>
          
          <p id="bloodrelatives">
            "The 'degree of relationship' describes the proportion of genes shared
            by two blood relatives. A person's first degree relative is a parent,
            sibling, or child. A first degree relative shares about half of their
            genes with the person.
            <br/><br/>
            A second degree relative of a person is an uncle, aunt, nephew, niece,
            grandparent, grandchild or half- sibling. A second degree relative 
            shares about one quarter of their genes with the person."
            <span class="evidence" title="nhsgenetics">(NHS NGGEC no year)</span>
          </p>
          
          
          <h4>Graft versus Host Disease, Transfusion Associated (TA-GvHD)</h4>
          
          <p id="gvhd">
          
            "TA-GvHD is a very rare but usually fatal complication following
            transfusion of lymphocyte-containing blood components. [---] The
            risk associated with an individual transfusion depends on the 
            number and viability of contaminating lymphocytes, susceptibility
            of the recipient's immune system to their engraftment and degree 
            of immunological (HLA) disparity between donor and patient."
            <span class="evidence" title="bcsh2010">(BCSH 2010, p.37)</span>
            <br/><br/>
            "Transfused donor lymphocytes which are compatible with the recipient,
            but which recognise the recipient as foreign, can engraft and initiate
            TA-GvHD. Patients develop skin rash, diarrhoea and abnormal liver
            function, and deteriorate, with bone marrow failure and death from
            infection usually within two to three weeks of transfusion."
            <span class="evidence" title="htm2007">(HTM 2007, p.41)</span>
            <br/><br/>
            "Patients at risk are immunocompromised or those who receive 
            transfusion from a first- or second-degree relative (due to 
            the sharing of an HLA haplotype)." <span class="evidence" title="htm2007">(HTM 2007, p.41)</span>
            <br/><br/>
            Irradiation of cellular blood components intended for at risk patients
            prevent TA-GvHD. 
          </p>
          
          <h4>Irradiation, of blood cellular components</h4>
          
          <p id="irradiation">
            "The major technology for preventing TA-GvHD is irradiation of blood 
            components to inactivate residual lymphocytes. Gamma rays and X-rays
            are similar in their ability to inactivate T lymphocytes in blood 
            components at a given absorbed dose." 
            <span class="evidence" title="bcsh2010">(BCSH 2010, p. 41)</span>
            <br/><br/>
            "In the UK, a minimum of 25 Gy is recommended, but with the dose to 
            any bag in the container not exceeding 50 Gy. To ensure this dose
            distribution is achieved, consultation with supporting physicists
            is mandatory." <span class="evidence" title="bcsh2010">(BCSH 2010, p. 41)</span>
            <br/><br/>
            "For at-risk patients, all red cell, platelet and granulocyte 
            concentrates should be irradiated except cryopreserved red cells after
            deglycerolization. It is not necessary to irradiate fresh frozen plasma,
            cryoprecipitate or fractionated plasma products."
            <span class="evidence" title="bcsh2010">(BCSH 2010, p. 36)</span>
          </p>
          
          
          <h4>Leucocyte depletion, Universal</h4>
          
          <p id="leucodepletion">
            "Removal of leucocytes to a level of less than one million per component
            by filtration or during collection of blood components by apheresis
            is normal practice in a number of EU countries. Advantages of 
            leucodepletion include a marked reduction in alloimmunisation to
            HLA antigens and in the risk of infection by intracellular viruses
            such as cytomegalovirus. Leucodepletion of red cells may also be 
            associated with improved outcomes in some groups of patients." OBU 2010
            <span class="evidence" title="nhsgenetics">(NHS NGGEC no year)</span>
            <br/><br/>
            With the introduction of universal leucodepletion in 1999, all 
            red cells and platelets supplied through the UK blood services
            are leucocyte depleted.
            <span class="evidence" title="sabto2012">(SaBTO 2012, p.1)</span>
          </p>
          
          
          
        </div>
        
        <h3>Navigation</h3>
        
        <a href="#" style="padding: 0.8em;" data-role="button" data-theme="b" class="hidden active" onclick="$('.toc').toggle('slow');"><i class="fa fa-ln">&#xf0c9;</i> Table of contents</a>
       
        <div class="toc">
          <ul data-role="listview" data-inset="true" data-dividertheme="b">
            <li><a href="#learn">1.1 Learning objectives</a></li>
            <li><a href="#ta-gvhd">1.2 Transfusion-associated Graft versus Host Disease</a></li>
            <li><a href="#tt-cmv">1.3 Transfusion-transmitted Cytomegalovirus infection</a></li>
            <li><a href="#error" >1.4 Errors in provision of special requirements</a></li>
            <li><a href="#summary">1.5 Summary</a></li>
            <li data-theme="b"><a href="#reference" class="active">1.6 Further reading</a></li>
          </ul>
        </div>
        
        <a href="#tt-cmv" style="padding: 0.8em;" data-role="button" data-theme="b" data-inline="true" data-rel="back" class="active"><i class="fa fa-ln">&#xf053;</i> Back</a>
        <a href="#summary" style="float:right; padding: 0.8em;" data-role="button" data-theme="b" data-inline="true" class="active">Next <i class="fa fa-ln">&#xf054;</i></a>
        
        <a href="#" data-role="button" data-theme="b" onclick="$(window).scrollTop(0);" class="active">Back to top <i class="fa fa-ln">&#xf0d8;</i></a>
        
        
      </div>
      
      <div data-role="footer" data-position="fixed" data-tap-toggle="false" data-theme="b">
        <div data-role="navbar">
          <ul>
            <li><a href="#home" class="navtab inactive"><i class="fa fa-2x">&#xf015;</i> Home</a>
            </li>
            <li><a href="#learn" class="navtab active"><i class="fa fa-2x glow">&#xf19d;</i>Learn</a>
            </li>
            <li><a href="#indications" class="navtab inactive"><i class="fa fa-2x">&#xf0f1;</i> Indications</a>
            </li>
          </ul>
        </div>
      </div>
    </div>
    
    <div data-role="page" id="reference" data-title="References">
      
      <div data-role="header" class="inactive" data-theme="b">
        
        <h3 class="headerlogo active"><i class="fa fa-ln glow">&#xf19d;</i>References </h3>
        <div class="submenu inactive">
          <a href="#summary" data-role="button" data-rel="back" class="float-left"><i class="fa fa-ln">&#xf053;</i> Back</a>
          <a href="#quickfind" data-role="button">QuickFind <i class="fa fa-ln">&#xf002;</i></a>
        </div>
      </div>

      <div role="main" class="ui-content" data-searchable="3">
            
        <h3>
          References
        </h3>
        <div style="margin-left: 1em;">
          <p id="sabto2012">
            Advisory Committee on the Safety of Blood, Tissues and Organs (SaBTO)
            (2012) Position statement on cytomegalovirus tested blood components.
            <a href="https://www.gov.uk/government/publications/sabto-report-of-the-cytomegalovirus-steering-group" target="_blank">Open</a>
          </p>
          
          <p id="sabto2012b">
            Advisory Committee on the Safety of Blood, Tissues and Organs (SaBTO)
            (2012) Report of the Cytomegalovirus Steering Group
            <a href="https://www.gov.uk/government/publications/sabto-report-of-the-cytomegalovirus-steering-group" target="_blank">Open</a>
          </p>
          
          <p  id="shot2012">
            Bolton-Maggs, P (Ed) and Cohen, H (2012) on behalf of the Serious Hazards
            of Transfusion (SHOT) Steering Group. The 2011 Annual SHOT Report.
            <a href="http://www.shotuk.org/shot-reports/shot-annual-report-summary-2011/" target="_blank">Open</a>
          </p>
              
          <p id="shot2013">
            Bolton-Maggs P (Ed), Poles D, Watt A, Thomas D and Cohen H (2013) on behalf
            of the Serious Hazards of Transfusion (SHOT) Steering Group. The 2012
            Annual SHOT Report.<a href="http://www.shotuk.org/shot-reports/report-summary-and-supplement-2012/" target="_blank">Open</a>
          </p>
          
          <p id="ukbts2012">
            Joint UKBTS / HPA Professional Advisory Committee (2012) Position Statement
            on Granulocyte Therapy. Revised by Edwin Massey, Simon Stanworth and
            Rebecca Cardigan at the request of the Standing Advisory Committee on Blood
            Components. <a href="http://www.transfusionguidelines.org.uk/index.aspx?Publication=DL&amp;pageid=1336" target="_blank">Open</a>
          </p>
  
          <p id="htm2007">
            McClelland DBL (ed) (2007) Handbook of Transfusion Medicine, 4th Ed.
            Published in the UK by The Stationary Office. <a href="http://www.transfusionguidelines.org.uk/index.aspx?Publication=HTM" target="_blank">Open</a>
          </p>
              
          <p id="obu2010">
            McClelland DBL, Pirie E, Franklin IM (2010) for the EU Optimal Use of Blood
            Project Partners. The Optimal Blood Use Manual. Published by Scottish
            National Blood Transfusion Service. 
              <a href="http://www.optimalblooduse.eu" target="_blank">Open</a>
          </p>
          
          <p id="mesh2013">
            Medical Subject Headings (2013) published by the U.S. National Library of
            Medicine, National Institutes of Health. 
              <a href="http://www.nlm.nih.gov/mesh/2013/mesh_browser/" target="_blank">Open</a>
          </p>
          
          <p id="nhsgenetics">
            NHS National Genetics and Genomics Education Centre,
            glossary item "First-degree relative".
              <a href="http://www.geneticseducation.nhs.uk/genetics-glossary/181-first-degree-relative" target="_blank">Open</a>
          </p>
          
          <p id="phil1986">
            Public Health Image Library (PHIL), 1986, Centres for Disease Control and Prevention.
              <a href="http://phil.cdc.gov/phil/details.asp?pid=14429" target="_blank">Open</a>
          </p>
          
          <p id="shot2008">
            Taylor C, Cohen H, Jones H, et al (2008), on behalf of the Serious Hazards
            of Transfusion (SHOT) Steering Group. The 2007 Annual SHOT Report.
            
            <a href="http://www.shotuk.org/shot-reports/reports-and-summaries-2007/" target="_blank">Open</a>
          </p>
          
          <p  id="shot2009">
            Taylor C (Ed.), Cohen H, Mold D, Jones H, et al (2009), on behalf of the
            Serious Hazards of Transfusion (SHOT) Steering Group. The 2008 Annual SHOT
            Report. <a href="http://www.shotuk.org/shot-reports/reports-and-summaries-2008/" target="_blank">Open</a>
          </p>
              
          <p  id="shot2010">
            Taylor C (Ed.), Cohen H, Mold D, Jones H, et al (2010), on behalf of the
            Serious Hazards of Transfusion (SHOT) Steering Group. The 2009 Annual SHOT
            Report. <a href="http://www.shotuk.org/shot-reports/report-and-summary-2009/" target="_blank">Open</a>
          </p>
          
          <p id="bcsh2010">
            Treleaven, J., Gennery, A., Marsh, J., Norfolk, D., Page, L., Parker, A.,
            Saran, F., Thurston, J. and Webb, D. (2011), Guidelines on the use of
            irradiated blood components prepared by the British Committee for Standards
            in Haematology blood transfusion task force. British Journal of
            Haematology, 152: 35-51. doi: 10.1111/j.1365-2141.2010.08444.x
            <a href="http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2010.08444.x/full" target="_blank">Open</a>
          </p>
          
        </div>
        
        <p>All links open in a new window. </p>
        
        
        <h3>Navigation</h3>
        
        <a href="#" style="padding: 0.8em;" data-role="button" data-theme="b" class="hidden active" onclick="$('.toc').toggle('slow');"><i class="fa fa-ln">&#xf0c9;</i> Table of contents</a>
       
        <div class="toc">
          <ul data-role="listview" data-inset="true" data-dividertheme="b">
            <li><a href="#learn">1.1 Learning objectives</a></li>
            <li><a href="#ta-gvhd">1.2 Transfusion-associated Graft versus Host Disease</a></li>
            <li><a href="#tt-cmv">1.3 Transfusion-transmitted Cytomegalovirus infection</a></li>
            <li><a href="#error" >1.4 Errors in provision of special requirements</a></li>
            <li><a href="#summary">1.5 Summary</a></li>
            <li data-theme="b"><a href="#reference" class="active">1.6 Further reading</a></li>
          </ul>
        </div>
        
        <a href="#tt-cmv" style="padding: 0.8em;" data-role="button" data-theme="b" data-inline="true" data-rel="back" class="active"><i class="fa fa-ln">&#xf053;</i> Back</a>
        <a href="#summary" style="float:right; padding: 0.8em;" data-role="button" data-theme="b" data-inline="true" class="active">Next <i class="fa fa-ln">&#xf054;</i></a>
        
        <a href="#" data-role="button" data-theme="b" onclick="$(window).scrollTop(0);" class="active">Back to top <i class="fa fa-ln">&#xf0d8;</i></a>
        
        
      </div>
      
      <div data-role="footer" data-position="fixed" data-tap-toggle="false" data-theme="b">
        <div data-role="navbar">
          <ul>
            <li><a href="#home" class="navtab inactive"><i class="fa fa-2x">&#xf015;</i> Home</a>
            </li>
            <li><a href="#learn" class="navtab active"><i class="fa fa-2x glow">&#xf19d;</i>Learn</a>
            </li>
            <li><a href="#indications" class="navtab inactive"><i class="fa fa-2x">&#xf0f1;</i> Indications</a>
            </li>
          </ul>
        </div>
      </div>
    </div>
    
    
    
    
    
    
    <div data-role="page" id="quickfind" data-title="QuickFind">
      <div data-role="header" class="inactive" data-theme="b">
        
        <h3 class="headerlogo active"><i class="fa fa-ln glow">&#xf002;</i> QuickFind
        </h3>
        <div class="submenu inactive" style="text-align: left;">
          <a href="#" data-role="button" data-rel="back"><i class="fa fa-ln">&#xf053;</i> Back</a>
        </div>
      </div>
  
  		<div role="main" class="ui-content">
    		<h2>Search the app</h2>
        
        <form>
          <input data-type="search" id="quickfind-input">
        </form>
        
        <div id="searchlist" data-filter-reveal="true" data-filter="true" data-input="#quickfind-input">
        </div>

  		</div>
  		
  	</div>
    
    
    <script src="http://code.jquery.com/jquery-1.9.1.js"></script>
    <script src="footable.js" type="text/javascript"></script>
    <script src="app.js"></script>
    <script src="http://code.jquery.com/mobile/1.4.4/jquery.mobile-1.4.4.min.js"></script>
  </body>

</html>